Systematic SAR optimization of the GPR119 agonist lead 1, derived from an internal HTS campaign, led to compound 29. Compound 29 displays significantly improved in vitro activity and oral exposure, leading to GLP1 elevation in acutely dosed mice and reduced glucose excursion in an OGTT study in rats at doses ⩾10 mg/kg.
Keywords: GPCR agonists; GPR119; Tricyclic pyrazolopyrimidines; Type 2 diabetes.
Copyright © 2014 Elsevier Ltd. All rights reserved.